Product Substitution and Comparative Dynamics in the Indian Pharmaceutical Market

Pharmaceutical product substitution has become a central structural mechanism reshaping pricing, competition, and firm strategy within the Indian pharmaceutical market under an increasingly regulated healthcare environment. This study examines the regulatory, economic, and institutional determinants of generic and therapeutic substitution in India, with particular emphasis on how policy-driven mechanisms shape substitution outcomes across public and private healthcare systems. Using an analytical secondary-data design, the study draws on evidence from the National Pharmaceutical Pricing Authority (NPPA), Health Management Information System (HMIS), National List of Essential Medicines (NLEM), Competition Commission of India (CCI), and international benchmarks from the OECD and WHO. The findings show that generic medicines account for approximately 97% of pharmaceutical sales by volume in India (AIOCD-AWACS), yet represent only around 38% of total market value, yielding an Effective Substitution Efficiency Ratio (ESER) of 0.39, substantially lower than the OECD average of 0.77. While generic entry results in 30–50% revenue erosion for branded products and generics priced 50–80% lower rapidly gain substantial volume share, economic substitution remains incomplete. Institutional procurement systems achieve significantly greater price efficiency, with procurement prices nearly 1.9 times lower than private retail prices for identical molecules. Moreover, extensive brand proliferation is associated with high price dispersion—up to 200%—without commensurate gains in competition. Overall, pharmaceutical substitution in India is institutionally driven rather than market-led, delivering affordability gains but limited value-based substitution, with important implications for health policy and industry strategy.